MoonLake Immunotherapeutics <MLTX.O>: H.C. Wainwright raises target price to $50 from $45
MLTX•Related News
YXT.com 1H FY26 net loss narrows 80.5% to RMB 14.4 million; revenue rises 6% to RMB 162.1 million
YXT•
Dillard’s FY26 Q2 net income rises 34% to $97.7 million; net sales slip 0.4% to $1.51 billion
DDS•
Lithium Americas publishes investor presentation on Thacker Pass Phase 1 construction, path to U.S. lithium production
LAC•
Pyxis Oncology Q2 Net Income USD -25.346 Million
PYXS•
Yarrow Bioscience Q2 FY26 net loss narrows to $6.51 million; R&D expenses rise to $4.94 million
YARW•